• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Results from the PRECISE Study: Repeat Prenatal Corticosteroid Treatment for Preterm Birth

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Unclear whether repeat courses of prenatal corticosteroids can reduce risks and outcomes associated with preterm birth
  • Crowther et al. (PLoS Medicine, 2019) assessed whether the effects of repeat corticosteroid treatments in women with an ongoing risk of preterm birth effects varied depending on participant and treatment factors

METHODS:

  • Individual participant meta-analysis
    • Prenatal Repeat Corticosteroid International IPD-MA Study (PRECISE)
  • Study inclusion criteria
    • RCTs including women at risk of preterm birth
    • Participants had received single course of prenatal corticosteroid seven or more days prior
    • Outcomes compared with either placebo or no placebo
  • Primary outcomes
    • Infant outcomes: Overall serious outcome | Use of respiratory support | Birth weight z-scores
    • Childhood outcomes: Death | Neurosensory disability
    • Maternal outcomes: Maternal sepsis
  • Serious outcomes: Death | Severe respiratory disease | Grade 3 or 4 IVH | Chronic lung disease (oxygen dependent at 36 weeks postmenstrual age) | NEC | Stage 3 or worse ROP | Cystic periventricular leucomalacia)
  • Data collection and analysis
    • Studies found using the Cochrane Pregnancy and Childbirth search strategy
    • Individual patient data requested from investigators
    • Risk of bias was assessed using criteria from the Cochrane Collaboration
  • Authors sought to determine if the following individual characteristics impacted treatment effects 
    • Reason for preterm birth (e.g., hemorrhage vs preterm labor)
    • Gestational age at time of repeat prenatal
    • Number of repeat doses
    • Amount of time prior to birth

RESULTS:

  • 11 trials | 4,857 | 5,915 infants
    • Mean gestational age at entry: 27.4 weeks to 30.2 weeks
  • No difference in infants with a serious outcome
    • Relative risk [RR] 0.92 (95% CI, 0.82 to 1.04)
  • Respiratory support less common in infants exposed to repeat corticosteroid
    • RR 0.91 (95% CI 0.85 to 0.97)
    • NNT to prevent respiratory support: 21 (95% CI 14 to 41)
    • Beneficial impact increased with number of doses
  • Birth weight z-scores were lower in infants exposed to repeat corticosteroid
    • Mean difference −0.12 (95%CI −0.18 to −0.06)
    • The more doses, the greater the negative impact on weight, length and head circumference
  • Maternal and child outcomes: No differences were identified
  • Treatment effect did not vary based on  
    • Reason for preterm birth risk
    • Number of fetuses
    • Gestational age at treatment
    • Time prior to birth of last dose
  • Not all subgroups could be assessed due to low ‘n’

CONCLUSION:

  • Repeat antenatal corticosteroids for those at increased risk of preterm birth
    • Reduces use of infant respiratory support
    • Lowers weight, length and head circumference
  • The authors conclude that

To provide clinical benefit with the least effect on growth, the number of repeat treatment courses should be limited if possible. We suggest a maximum of three repeat treatments and a total dose of between 24 mg and 48 mg.

Learn More – Primary Sources:

Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Antenatal Corticosteroids – When to Administer?
In Women at Risk of Late Preterm Delivery, is Corticosteroid Therapy Still Cost-Effective?
Is There Value to the Use of Corticosteroids in Women with Short Cervix Who Are Asymptomatic?
Does FGR Impact Neurocognitive Function in Childhood Following Repeat Antenatal Betamethasone Dosing?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site